News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Trending on PharmExec
1
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
2
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
3
Pharmaceutical Executive Daily: FDA Approves Simtriyo
4
Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies
5